{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T17:17:47Z","timestamp":1709313467404},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T00:00:00Z","timestamp":1224115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00120-008-1797-z","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T23:38:23Z","timestamp":1224027503000},"page":"1582-1587","source":"Crossref","is-referenced-by-count":3,"title":["Grundlagen der Phosphodiesterase-5- (PDE5-)Inhibitoren","The basics of phosphodiesterase type 5 (PDE5) inhibition in urology"],"prefix":"10.1007","volume":"47","author":[{"given":"A.J.","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"\u00dcckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"1797_CR1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","volume":"108","author":"Essayan","year":"2001","unstructured":"Essayan DM (2001) Cyclic nucleotide phosphodiesterases. J Allerg Clin Immunol 108: 671\u2013680","journal-title":"J Allerg Clin Immunol"},{"key":"1797_CR2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/mf.2005.27.2.876285","volume":"27","author":"Gupta","year":"2005","unstructured":"Gupta R, Kumar G, Kumar RS (2005) An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterase and drug selectivity. Methods Find Exp Clin Pharmacol 27: 101\u2013118","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1797_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-2952(92)90654-2","volume":"43","author":"Hall","year":"1992","unstructured":"Hall IP, Hill SJ (1992) Effect of isoenzyme selective phosphodiesterase inhibitors on bovine tracheal smooth muscle tone. Biochem Pharmacol 43: 15\u201317","journal-title":"Biochem Pharmacol"},{"key":"1797_CR4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/0002-8703(91)90827-5","volume":"121","author":"Braunwald","year":"1991","unstructured":"Braunwald E (1991) Intravenous milrinone: therapeutic responses in heart failure. Am Heart J 121: 1937\u20131938","journal-title":"Am Heart J"},{"key":"1797_CR5","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/0002-8703(91)90078-V","volume":"121","author":"diBianco","year":"1991","unstructured":"diBianco R (1991) Acute positive inotropic intervention: the phosphodiesterase inhibitors. Am Heart J 121: 1871\u20131875","journal-title":"Am Heart J"},{"key":"1797_CR6","first-page":"6","volume":"7","author":"Stief","year":"1995","unstructured":"Stief CG, \u00dcckert S, Truss MC et al. (1995) Cyclic nucleotide phosphodiesterases in human cavernous smooth muscle: characterization and functional effects of various PDE-inhibitors in vitro and in vivo. Int J Impot Res 7(Suppl 1): 6","journal-title":"Int J Impot Res"},{"key":"1797_CR7","first-page":"495","volume":"151","author":"\u00dcckert","year":"1994","unstructured":"\u00dcckert S, Stief CG, Becker AJ et al. (1994) The effect of the specific phosphodiesterase III - inhibitor milrinone on human and rabbit erectile tissue. J Urol A 151(Suppl): 495","journal-title":"J Urol A"},{"key":"1797_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5347(01)66430-9","volume":"155","author":"Boolell","year":"1996","unstructured":"Boolell M, Gepi-Attee S, Gingell CJ, Allen M (1996) UK 92 480, a new oral treatment for erectile dysfunction. A double-blind, placebo-controlled cross-over study demonstrating dose response with rigiscan and efficacy with outpatient diary. J Urol A 155(Suppl): 495","journal-title":"J Urol A"},{"key":"1797_CR9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425255.1.2.283","volume":"1","author":"Francis","year":"2005","unstructured":"Francis SH, Corbin JD (2005) Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 1: 283\u2013293","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1797_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00007090","volume":"19","author":"\u00dcckert","year":"2001","unstructured":"\u00dcckert S, K\u00fcthe A, Stief CG, Jonas U (2001) Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19: 14\u201322","journal-title":"World J Urol"},{"key":"1797_CR11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.ijir.3900726","volume":"13","author":"Saenz","year":"2001","unstructured":"Saenz de Tejada I, Angulo J, Cuevas P et al. (2001) The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 13: 282\u2013290","journal-title":"Int J Impot Res"},{"key":"1797_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425255.1.2.295","volume":"1","author":"Sommer","year":"2005","unstructured":"Sommer F (2005) Potency and selectivity of vardenafil: a phosphodiesterase type 5 inhibitor. Expert Opin Drug Metab Toxicol 1: 295\u2013301","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1797_CR13","first-page":"64","volume":"13","author":"Mazzu","year":"2001","unstructured":"Mazzu A, Nicholls A, Zinny M (2001) Vardenafil: a new highly selective PDE5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged subjects. Int J Impot Res 13(Suppl 5): 64","journal-title":"Int J Impot Res"},{"key":"1797_CR14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1569-9056(02)80588-7","volume":"1","author":"Thadani","year":"2002","unstructured":"Thadani U, Mazzu A (2002) Exercise-induced ischemia was not adversely affected by vardenafil during exercise stress test in men with coronary artery disease. Eur Urol 1(Suppl 1): 151","journal-title":"Eur Urol"},{"key":"1797_CR15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1742-1241.2002.tb11260.x","volume":"56","author":"Eardly","year":"2002","unstructured":"Eardly I, Cartledge J (2002) Tadalafil (CIALIS) for men with erectile dysfunction. Int J Clin Pract 56: 300\u2013304","journal-title":"Int J Clin Pract"},{"key":"1797_CR16","doi-asserted-by":"crossref","first-page":"31469","DOI":"10.1074\/jbc.M003041200","volume":"275","author":"Yuasa","year":"2000","unstructured":"Yuasa K, Kotera J, Fujishige K et al. (2000) Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275: 31469\u201331479","journal-title":"J Biol Chem"},{"key":"1797_CR17","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","volume":"168","author":"Brock","year":"2002","unstructured":"Brock GB, McMahon CG, Chen KK et al. (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168: 1332\u20131336","journal-title":"J Urol"},{"key":"1797_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1569-9056(02)80240-8","volume":"1","author":"Gebekor","year":"2001","unstructured":"Gebekor E, Bethell S, Fawcett L (2001) Selectivity of sildenafil and other phosphodiesterase type 5 inhibitors against all human phosphodiesterase families. Eur Urol 1(Suppl 1): 63","journal-title":"Eur Urol"},{"key":"1797_CR19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1520-765X(02)90050-7","volume":"4","author":"Emmick","year":"2002","unstructured":"Emmick JT, Stuewe SR, Mitchell M (2002) Overview of the cardiovascular effects of tadalafil. Eur Heart J 4(Suppl H): 32\u201347","journal-title":"Eur Heart J"},{"key":"1797_CR20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.ijir.3901331","volume":"17","author":"Kang","year":"2005","unstructured":"Kang KK, Yu JY,Yoo M, Kwon JW (2005) The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res 17: 409\u2013416","journal-title":"Int J Impot Res"},{"key":"1797_CR21","first-page":"661","volume":"7","author":"Salem","year":"2006","unstructured":"Salem EA, Kendirci M, Hellstrom WJ (2006) Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 7: 661\u2013669","journal-title":"Curr Opin Investig Drugs"},{"key":"1797_CR22","unstructured":"VIVUS Inc. (2008) Data on file. VIVUS Inc., Mountain View, CA, USA (http:\/\/www.vivus.com)"},{"key":"1797_CR23","first-page":"697","volume":"29","author":"Bayes","year":"2006","unstructured":"Bayes M, Rabasseda X, Prous JR (2006) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 29: 697\u2013673","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1797_CR24","first-page":"105","volume":"70","author":"de","year":"2007","unstructured":"de Nucci G, Lorenzetti R, Okuyama CE et al. (2007) Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Urology 70 (Suppl 3A): 105","journal-title":"Urology"},{"key":"1797_CR25","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"Galie","year":"2006","unstructured":"Galie N, Ghofrani HA, Torbicki A et al. (2006) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148\u20132157","journal-title":"N Engl J Med"},{"key":"1797_CR26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.ijir.3901465","volume":"18","author":"Foresta","year":"2006","unstructured":"Foresta C, Ferlin A, de Toni L et al. (2006) Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 18: 484\u2013488","journal-title":"Int J Impot Res"},{"key":"1797_CR27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","volume":"166","author":"Caglayan","year":"2006","unstructured":"Caglayan E, Huntegeburth M, Karasch T et al. (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166: 231\u2013233","journal-title":"Arch Intern Med"},{"key":"1797_CR28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"Ferrini","year":"2006","unstructured":"Ferrini MG, Kovanecz I, Nolazco G et al. (2006) Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2018s disease. BJU Int 97: 625\u2013633","journal-title":"BJU Int"},{"key":"1797_CR29","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.eururo.2006.05.025","volume":"50","author":"\u00dcckert","year":"2006","unstructured":"\u00dcckert S, Hedlund P, Andersson KE et al. (2006) Update on phosphodiesterase (PDE) isoenzymes as pharmacological targets in urology: present and future. Eur Urol 50: 1194\u20131207","journal-title":"Eur Urol"},{"key":"1797_CR30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00345-006-0121-z","volume":"24","author":"\u00dcckert","year":"2006","unstructured":"\u00dcckert S, Mayer ME, Jonas U, Stief CG (2006) Potential future options in the pharmacotherapy of female sexual dysfunction. World J Urol 24: 630\u2013638","journal-title":"World J Urol"},{"key":"1797_CR31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/GCO.0b013e3282f1c733","volume":"19","author":"Mayer","year":"2007","unstructured":"Mayer ME, Bauer R, Schorsch I et al. (2007) Female sexual dysfunction: what\u2019s new? Curr Opin Obstet Gynecol 19: 536\u2013540","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1797_CR32","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","volume":"53","author":"Stief","year":"2008","unstructured":"Stief CG, Porst H, Neuser D et al. (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236\u20131244","journal-title":"Eur Urol"},{"key":"1797_CR33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","volume":"177","author":"McVary","year":"2007","unstructured":"McVary KT, Monnig W, Camps JL et al. (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071\u20131077","journal-title":"J Urol"},{"key":"1797_CR34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","volume":"177","author":"McVary","year":"2007","unstructured":"McVary KT, Roerborn CG, Kaminetsky JC et al. (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401\u20131407","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-008-1797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-008-1797-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-008-1797-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T16:29:22Z","timestamp":1709310562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-008-1797-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,16]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s00120-008-1797-z","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,16]]}}}